Abstract
10502 Background: CCS are at increased risk of therapy-related PM but contribution of genetic factors is unknown. Methods: Using Affymetrix 6.0 SNP array, treatment exposures [cumulative alkylating agents (AA), ovarian radiotherapy (RT) dose] and clinically-assessed PM status (menopause < 40 years), a genome-wide association analysis was conducted using logistic regression in SJLIFE. A cluster of most statistically significant SNPs on chr4 was further examined, stratifying by ovarian RT and AA. Replication was performed using self-reported PM in CCSS. Results: PM was diagnosed in 30 of 805 SJLIFE female survivors. A loci of 13 SNPs in 4 linkage disequilibrium blocks (mean r2 = 0.51) in the upstream regulatory region of Neuropeptide Receptor 2 ( NPY2R) was identified with a minimum p-value of 3.3x10-7 (all <10-5). ENCODE gene expression, motifs, and chromatin remodeling data suggest these SNPs alter transcription factor binding sites, potentially disrupting neuroendocrine events necessary for ovulation. Among CCS exposed to ovarian RT, homozygous carriers of a risk profile (RP) defined by 4 of the 13 SNPs, found in over half of the survivors with clinically-diagnosed PM and 1 in 7 in the general population, significantly increased PM risk (odds ratio (OR) 25.8, p=5.4x10-5) (Table). This finding was replicated using self-reported PM status of 1644 survivors in CCSS (OR 4.2, p=4.6x10-4). Prediction of clinically-diagnosed PM (in the SJLIFE discovery cohort) improved by adding the RP to the model with age and treatment (area under ROC curve 0.84 vs. 0.93, p=0.011). Conclusions: The common RP is associated with PM risk in pediatric cancer survivors and may have potential for clinical application. [Table: see text]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.